Inspired by the reinvigoration the field has seen over the last 2 years, the Targeted Radiopharmaceuticals (TRP) Summit is the primary platform for industry-led discussion of the challenges and opportunities facing developers of theranostic radio ligand therapies.

Following the hugely successful meeting of key opinion leaders in 2019, this conference returns with a wider array of insights from recent case studies to help you accelerate the development of the next-generation of radioligand therapies from clinical approval to commercialisation.